Chinook marks an ignominious end for Sting
Aduro finally runs up the white flag on Sting agonism, and becomes a listed shell for Chinook Therapeutics.
After Takeda endorsement Curadev’s Sting attracts Bayer
The coronavirus pandemic notwithstanding, Curadev snares its second Sting partner.
Does amount matter when it comes to a biotech IPO?
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
Abbvie hopes to turn around the fortunes of Sting
Continued interest in the Sting pathway might come as a surprise, though secrecy suggests that asset prices are failing.
Asco 2019 event analyser – low-key meeting belies some huge stock moves
Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.
Asco 2019 – Abstract drop fires the starting gun
Amgen’s KRAS inhibitor, Macrogenics’ breast cancer project and Roche’s entrectinib stand out as the curtain lifts on thousands of abstracts due to be presented at the…
SITC 2018 – The search for immuno-oncology combos continues
Once hotly tipped approaches from Aduro, Tesaro and Merck & Co might yet hold promise, but disappointing early data cuts have burst the bubble of investor…
Esmo 2018 – Adaptimmune gets the wooden spoon
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
